Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: Synthesis and cysteinyl proteinase inhibition

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 21, 2004, Pages 5689-5710

  Quibell, Martin ^a   Benn, Alex ^a   Flinn, Nick ^a   Monk, Tracy ^a   Ramjee, Manoj ^a   Wang, Yikang ^a   Watts, John ^a  

^a Amura Therapeutics Limited   (United Kingdom)

Author keywords

Anti resorptive; Bicyclic ketones; Cysteinyl proteinase inhibition

Indexed keywords

CYSTEINE PROTEINASE; PYRIDINE DERIVATIVE;

ARTICLE; CHIRALITY; CIS TRANS ISOMERISM; DRUG DESIGN; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; PROTEIN FOLDING; STEREOCHEMISTRY; THERMODYNAMICS;

ANIMALS; BICYCLO COMPOUNDS; CATTLE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; HUMANS; PROTEIN BINDING; PYRIDINES;

INSERTION SEQUENCES;

EID: 4644351694     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.07.054     Document Type: Article

References (75)

1. H.-H. Otto, and T. Schirmeister Chem. Rev. 97 1997 133
2. D.F. Veber, and S.K. Thompson Curr. Opin. Drug Discov. Dev. 3 2000 362 369
3. H.A. Chapman, R.J. Riese, and G.-P. Shi Annu. Rev. Physiol. 59 1997 63
4. F. Lecaille, J. Kaleta, and D. Brömme Chem. Rev. 102 2002 4459
5. D. Brömme, and J. Kaleta Curr. Pharm. Des. 8 2002 1639 1658
6. A.J. Barrett, N.D. Rawlings, and J.F. Woessner Handbook of Proteolytic Enzymes 1998 Academic New York
7. N.A. Thornberry Chem. Biol. 5 5 1998 R97 R103
8. R. Leung-Toung, W. Li, T.F. Tam, and K. Karimian Curr. Med. Chem. 9 2002 979
9. A.A. Hernandez, and W.R. Roush Curr. Opin. Chem. Biol. 6 2002 459
10. W. Kim, and K. Kang Expert Opin. Ther. Patents 12 3 2002 419
11. J. Watts, A. Benn, N. Flinn, T. Monk, M. Ramjee, P. Ray, Y. Wang, and M. Quibell Bioorg. Med. Chem. 12 2004 2903
12. R.W. Marquis, Y. Ru, J. Zeng, R.E. Lee Trout, S.M. LoCastro, A.D. Gribble, J. Witherington, A.E. Fenwick, B. Garnier, T. Tomaszek, D. Tew, M.E. Hemling, C.J. Quinn, W.W. Smith, B. Zhao, M.S. McQueney, C.A. Janson, K. D'Alessio, and D.F. Veber J. Med. Chem. 44 2001 725 and references cited therein
13. R.W. Marquis, Y. Ru, S.M. LoCastro, J. Zeng, D.S. Yamashita, H.-J. Oh, K.F. Erhard, L.D. Davis, T.A. Tomaszek, D. Tew, K. Salyers, J. Proksch, K. Ward, B. Smith, M. Levy, M.D. Cummings, R.C. Haltiwanger, G. Trescher, B. Wang, M.E. Hemling, C.J. Quinn, H.-Y. Cheng, F. Lin, W.W. Smith, C.A. Janson, B. Zhao, M.S. McQueney, K. D'Alessio, C.-P. Lee, A. Marzulli, R.A. Dodds, S. Blake, S.-M. Hwang, I.E. James, C.J. Gress, B.R. Bradley, M.W. Lark, M. Gowen, and D.F. Veber J. Med. Chem. 44 2001 1380 and references cited therein
14. A.E. Fenwick, A.D. Gribble, R.J. Ife, N. Stevens, and J. Witherington Bioorg. Med. Chem. Lett. 11 2001 199
15. J.F. Morrison, and C.T. Walsh Adv. Enzymol. Relat. Areas Mol. Biol. 61 1988 201
16. W.X. Tian, and C.L. Tsou Biochemistry 21 5 1982 1028
17. See: (a) Quibell, M. Patent WO 02/057270
18. (b) Quibell, M.; Ray, P. C.; Watts, J. P. Patent WO 04/007501
19. E.L. Eliel, S.H. Wilen, and L.N. Mander Stereochemistry of Organic Compounds 1994 Wiley New York pp 1-1267
20. E.L. Eliel Stereochemistry of Carbon Compounds 1962 McGraw-Hill New York pp 1-486
21. A.T. Blomquist, and J. Kwiatek J. Am. Chem. Soc. 73 1951 2098
22. G. Mann Z. Chem. 6 3 1966 106
23. W. Reppe, O. Schlichting, K. Klager, and T. Toepel Liebigs Ann. Chem. 560 1948 1
24. A. Spelbos, F.C. Mijlhoff, W.H. Bakker, R. Baden, and L. Van den Enden J. Mol. Struct. 38 1977 155
25. N.L. Allinger, M. Nakazaki, and V. Zalkow J. Am. Chem. Soc. 81 1959 4074
26. J.W. Barrett, and R.P. Linstead J. Chem. Soc. 1936 611
27. C.C. Browne, and F.D. Rossini J. Phys. Chem. 64 1960 927
28. R.G. Salomon, D.J. Coughlin, S. Ghosh, and M.G. Zagorski J. Am. Chem. Soc. 104 4 1982 998
29. D.C. Owsley, and J.J. Bloomfield J. Chem. Soc. Sect. C 20 1971 3445
30. (c) No references are found for cis or trans-bicyclo[5.2.0]nonan-6-one although a CAS registry is present 105104-52-7
31. No references are found for trans-bicyclo[3.3.0]octan-2-one whilst the cis isomer is well known, for example, see: A.C. Cope, H.H. Lee, and H.E. Petree J. Am. Chem. Soc. 80 1958 2849
32. N.L. Allinger, and M.T. Tribble Tetrahedron 28 1972 1191
33. H.C. Brown, and E. Negishi J. Chem. Soc., Chem. Commun. 1968 594
34. H.O. House, and G.H. Rasmusson J. Org. Chem. 28 1963 31
35. D.L. Boger, and R.J. Mathvink J. Org. Chem. 53 1988 3379
36. P.W. Concannon, and J. Ciabattoni J. Am. Chem. Soc. 95 10 1973 3284 and references cited therein
37. U.P. Dhokte, P.M. Pathare, V.K. Mahindroo, and H.C. Brown J. Org. Chem. 63 1998 8276
38. 2 ketone carbonyl, heteroatoms as appropriate, the enol intermediate and finally through si and re stereofacial addition of methanethiol as a model of the proteinase bound intermediate hemithioketal. Each compound was generated in ChemDraw Ultra (v6.0, CambridgeSoft Corp.), then copy and pasted into Chem3D Pro (v5.0, CambridgeSoft Corp.) for an MM2 energy minimisation (RMS gradient = 0.1). The 'total energy' was then calculated for each minimised conformer, which relates to the total steric energy of the conformation and hence the relative stability of the conformer
39. It cannot be assumed that the literature detailed relative stabilities for carbocycle and ketocarbocycles are conserved upon the introduction of the heteroatoms into ketoheterocycles 4-8. Indeed, literature shows that certain heterocyclic analogues of bicyclo[3.3.0]octane exist in both cis and trans-fused conformations exist, for example, see: L.N. Owen, and A.G. Peto J. Chem. Soc. 1955 2383
40. A clear example of the point made in Ref. 16 is shown by the stable 5,5-bicycle detailed by GSK that is trans-fused and provides a generalised scaffold for serine protease inhibition. However, this scaffold does not contain a ketone functionality β to either bridgehead position and as such does not have a facile mechanism for loss of chirality through enolisation. See: A.D. Borthwick, S.J. Angier, A.J. Crame, A.M. Exall, T.M. Haley, G.J. Hart, A.M. Mason, A.M.K. Pennell, and G.G. Weingarten J. Med. Chem. 43 2000 4452
41. For example; K. Cathepsin, M.E. McGrath, J.L. Klaus, M.G. Barnes, and D. Brömme Nat. Struct. Biol. 4 2 1997 105
42. K. Cathepsin, F.X. Tavares, V. Boncek, D.N. Deaton, A.M. Hassell, S.T. Long, A.B. Miller, A.A. Payne, L.R. Miller, L.M. Shewchuk, K. Wells-Knecht, D.H. Willard Jr., L.L. Wright, and H.-Q. Zhou J. Med. Chem. 47 2004 588
43. S. Cathepsin, M.E. McGrath, J.T. Palmer, D. Brömme, and J.R. Somoza J. Prot. Sci. 7 1998 1294
44. F. Cathepsin, J.R. Somoza, J.T. Palmer, and J.D. Ho J. Mol. Biol. 322 2002 559
45. V. Cathepsin, J.R. Somoza, H. Zhan, K.K. Bowman, L. Yu, K.D. Mortara, J.T. Palmer, J.M. Clark, and M.E. McGrath Biochemistry 39 2000 12543
46. B. Cathepsin, P.D. Greenspan, K.L. Clark, R.A. Tommasi, S.D. Cowen, L.W. McQuire, D.L. Farley, J.H. van Duzer, R.L. Goldberg, H. Zhou, Z. Du, J.J. Fitt, D.E. Coppa, Z. Fang, W. Macchia, L. Zhu, M.P. Capparelli, R. Goldstein, A.M. Wigg, J.R. Doughty, R.S. Bohacek, and A.K. Knap J. Med. Chem. 44 26 2001 4524
47. R.L. Desjarlais, D.S. Yamashita, H.-J. Oh, I.N. Uzinskas, K.F. Erhard, A.C. Allen, R.C. Haltiwanger, B. Zhao, W.W. Smith, S.S. Abdel-Meguid, K. D'Alessio, C.A. Janson, M.S. McQueney, T.A. Tomaszek, M.A. Levy, and D.F. Veber J. Am. Chem. Soc. 120 1998 9114
48. A further example of the deleterious effects of P1 inhibitor secondary amide N-methylation is provided in Ref. 19. However, here only a fourfold loss in potency was observed, but this effect is detailed in a symmetrical inhibitor, which may potentially bind is a reverse manner, placing the N-methylated residue in an alternative proteinase binding pocket
49. For example see PDB codes, cathepsin K 1au0 (cis), 1au2 (cis), 1bgo (trans), 1mem (trans), 1nl6 (cis), 1nj7 (cis); cathepsin S 1ms6 (cis), 1npz (cis); cathepsin V 1fh0 (trans); cruzain 1aim (cis)
50. 25 was built to examine the products of both re and si stereofacial addition of the thiolate. As part of the assessment, calculations were performed on the isolated hemithioketal tetrahedral intermediate extracted from the predicted bound complex, to ascertain whether the binding model contained a reasonable energy inhibitor conformation. Conformer energy calculations were performed using CAChe (Conflex molecular mechanics engine, CAChe Group, Fujitsu). Additionally, the full modelling process considering each possible binding orientation was repeated using the literature cruzain X-ray structure 1aim and the mammalian cathepsin S X-ray structure 1ms6. Virtually identical conclusions concerning the preferred binding orientations described herein for the cathepsin K 1mem and 1au0 structures were found when substituting with the 1aim and 1ms6 structures
51. Predictions of likely binding conformations were performed as previously described (Ref. 5) and based solely upon comparison of the four possible re/si/prime side/nonprime side complexes for each bicycle. Major considerations in the development of a ranking for each possibility were the identification of a reasonable energy conformer for the inhibitor that retained a good hydrogen bonding network to the proteinase along with the absence of spatial clashes. The overall goodness of fit was assessed using the scoring functions generated by the software package 'GOLD 2.1' (Cambridge Crystallographic Data Centre) performing the calculations on the tetrahedral intermediates
52. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple J. Med. Chem. 45 2002 2615
53. K. Wisniewski, A.S. Koldziejczyk, and B. Falkiewicz J. Pept. Sci. 4 1 1998 1
54. S.A. Kolodziej, and G.R. Marshall Int. J. Pept. Prot. Res. 48 3 1996 274
55. 26 (trans giving C-2 at 67.7/67.9 and C-3 at 74.0/75.1 ppm; cis giving C-2 at 63.3/64.0 and C-3 at 71.3/72.0 ppm)
56. M. Dessolin, M.-G. Guillerez, N. Thieriet, F. Guibe, and A. Loffet Tetrahedron Lett. 36 32 1995 5741
57. For a general synthesis of Fmoc-aminoacid chloromethylketones from the corresponding diazomethylketones, see: J.L. Wood, L. Huang, and J.A. Ellman J. Comb. Chem. 5 2003 869
58. J. Drummond, G. Johnson, D.G. Nickell, D.F. Ortwine, R.F. Bruns, and B. Welbaum J. Med. Chem. 32 1989 2116
59. J.D. Scott, and R.M. Williams Tetrahedron Lett. 41 2000 8413
60. 3). Compounds (-)39, (-)40, 41 and (+)42 are enantiomers of the fully detailed compounds (+)33, (+)34, 35 and (-)13 and exhibited virtually identical NMR spectra to those annotated herein. Preparation of (-)39, (-)40, 41 and (+)42 are unpublished syntheses, although see Ref. a for preliminary disclosure
61. A.M. Murphy, R. Dagnino, P.L. Vallar, A.J. Trippe, S.L. Sherman, R.H. Lumpkin, S.Y. Tamura, and T.R. Webb J. Am. Chem. Soc. 114 1992 3156
62. For a thorough description of general multipin techniques, see: U. Grabowska, A. Rizzo, K. Farnell, and M. Quibell J. Comb. Chem. 2 5 2000 475
63. 2-COOH could be observed in most crude examples. This side-product, that derives from cleavage of the 3°amide bond, was readily removed by semi-preparative HPLC
64. 2-COOH product was the major mechanism of compound instability when assessed under acid, neutral and basic buffered conditions
65. Monocyclic analogues such as 49a,b were prepared for comparison following the general methods detailed in Quibell, M.; Taylor, S. Patent WO 00/69855
66. We are unable to further rationalise such a clear experimental result using the simple design tools and techniques described herein (Refs. 22,23)
67. G.B. Stroup, M.W. Lark, D.F. Veber, A. Bhattacharyya, S. Blake, L.C. Dare, K.F. Erhard, S.J. Hoffman, I.E. James, R.W. Marquis, Y. Ru, J.A. Vasko-Moser, B.R. Smith, T. Tomaszek, and M. Gowen J. Bone Miner. Res. 16 10 2001 1739
68. 6b,6c due to the earlier described broad elution profile and our failure to prepare the authentic trans standard for comparison. However, all our evidence, build upon the assumption that the cis and trans-fused diastereoisomers would show different and separable physical properties, gave no evidence for loss of β-chirality. For example, analogue 10 was prepared by the solid phase methods described herein on a 50 μM scale and purified by standard silica chromatography. TLC analysis of purified 10 exhibited a single tight UV positive spot that remained unchanged after three days in a range of organic and mixed organic/aqueous buffers. Additionally, NMR analysis of analogue 10 showed no evidence for the trans 5,5-bicycle even upon prolonged dissolution in NMR solvents. Broadly similar finding were evident for the corresponding 6,5-bicycle analogue 11
69. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Deliver. Rev. 23 1997 3
70. R.J. Riley Curr. Opin. Drug Discovery Dev. 4 1 2001 45
71. I.E. James, R.A. Dodds, D.L. Olivera, M.E. Nuttall, and M. Gowen J. Bone Miner. Res. 11 1996 1453
72. E. Atherton, and R.C. Sheppard Solid Phase Peptide Synthesis A Practical Approach 1989 IRL Oxford, U.K.
73. M. Meldal, and K. Breddam Anal. Biochem. 195 1991 141
74. A. Cornish-Bowden Fundamentals of Enzyme Kinetics 1995 Portland London
75. M.J. Bossard J. Biol. Chem. 271 21 1996 12517